Traws Pharma

Traws Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule antiviral therapies for critical global viral threats, with clinical programs targeting H5N1 bird flu, seasonal influenza, and COVID-19 / Long COVID. Lead candidate tivoxavir marboxil is being advanced for H5N1 bird flu with a human challenge trial planned in the United Kingdom, and ratutrelvir (TRX0) is being developed as a ritonavir-independent COVID-19 therapy. The company filed a registration statement for an unspecified securities offering in July 2026 and maintains a $50 million at-the-market facility from March 2025 to support clinical development.